KR890008137A - 3-[4(1-치환된-4-피페라지닐)부틸]-4-티아졸리디노 이의 제조방법 및 약제로서의 이의 용도 - Google Patents

3-[4(1-치환된-4-피페라지닐)부틸]-4-티아졸리디노 이의 제조방법 및 약제로서의 이의 용도 Download PDF

Info

Publication number
KR890008137A
KR890008137A KR1019880015210A KR880015210A KR890008137A KR 890008137 A KR890008137 A KR 890008137A KR 1019880015210 A KR1019880015210 A KR 1019880015210A KR 880015210 A KR880015210 A KR 880015210A KR 890008137 A KR890008137 A KR 890008137A
Authority
KR
South Korea
Prior art keywords
compound according
piperazinyl
butyl
compound
pharmaceutically acceptable
Prior art date
Application number
KR1019880015210A
Other languages
English (en)
Other versions
KR0130976B1 (ko
Inventor
제이.흐립 니콜라스
게라드 주르캑 죤
Original Assignee
도날드 알.톨센
훽스트-럿셀 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도날드 알.톨센, 훽스트-럿셀 파마슈티칼스 인코포레이티드 filed Critical 도날드 알.톨센
Publication of KR890008137A publication Critical patent/KR890008137A/ko
Application granted granted Critical
Publication of KR0130976B1 publication Critical patent/KR0130976B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

내용 없음

Description

3-[4(1-치환된-4- 피페라지닐)부틸]-4- 티아졸리디노 이의 제조방법 및 약제로서의 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 일반식(Ⅰ)의 화합물 및 이의 약제학적으로 허용되는 산 부가염.
    상기식에서, n은 0또는 1이고;
    U, V, W, Q, S 및 T는 각각 수소, 할로겐, 저급알킬, 하이드록시, 니트로, 저급알콕시, 아미노, 시아노 또는 트리플루오로메틸이고, m 은 1 또는 2이다)이며, R1및 R2는 각기 독립적으로 수소, 저급알킬 또는 아릴(여기에서, 아릴은 비치환된 페닐 그룹, 또는 저급알킬, 저급알콕시, 하이드록시, 할로겐, 저급알킬티오, 시아노, 아미노 및 트리플루오로메틸 중에서 각각 독립적으로 선택된 1, 2 또는 3개로 치환된 페닐 그룹을 의미한다)이거나, R1및 R2가 이들이 결합된 탄소와 함께는 사이클로펜탄, 사이클로헥산, 사이클로헵탄, 피란, 티오피란, 피롤리딘 또는 피페리딘 환을 형성하고, R3및 R4는 각기 독립적으로 수소 또는 저급알킬 이거나, R3및 R4가 이들이 결합된 탄소와 함께는 사이클로펜탄, 사이클로헥산, 사이클로헵탄, 피란, 티오피란, 피롤리딘 또는 피페리딘환을 형성한다.
  2. 제1항에 있어서, n 이 C 인 화합물.
  3. 제2항에 있어서, R1, R2, R3및 R4가 각기 독립적으로 수소, 저급알킬 또는 아릴이고, A 는 라디칼
    (여기에서, X, S 및 T는 상기에서 정의한 바와 같다)인 화합물.
  4. 제3항에 있어서, R1, R2, R3및 R4가 각기 독립적으로 수소, 메틸 또는 페닐이고, A가 라디칼
    (여기에서, X 는 메틸, 메톡시, Cl, F 또는 (F3이다)인 화합물.
  5. 제1항에 있어서, 2-메틸-3-[4-[1(4-플루오르페닐)-4-피페라지닐]부틸]-4-티아졸리디논인 화합물 및 이의 약제학적으로 허용되는 산 부가염.
  6. 제1항에 있어서, 3-[4-[1-(3-메틸페닐)-4-피페라지닐]-부틸]-4-티아졸리디논인 화합물 및 이의 약제학적으로 허용되는 산 부가염.
  7. 제1항에 있어서, 3-[4-(2,3디메틸페닐)-4-피페라지닐]-부틸]-4-티아졸리디논인 화합물 및 이의 약제학적으로 허용되는 산 부가염.
  8. 제1항에 있어서, 3-[4-[1-(4-클로로페닐)-4-피페라지닐]부틸]-4-티아졸리디논인 화합물 및 이의 약제학적으로 허용되는 산 부가염.
  9. 제1항에 있어서, 3-[4-[1-(1,2-벤즈이소티아졸-3-일)-4-피페라지닐]부틸]-5,5-디메틸-4-티아졸리디논 인 화합물 및 이의 약제학적으로 허용되는 산 부가염.
  10. 활성 성분으로서 제1항에 따르는 화합물 및 이에 적합한 담체를 함유함을 특징으로 하는 약제학적 조성물.
  11. 정신병 치료, 진통 및/또는 진경 활성을 지닌 약제를 제조하기 위한 제1항에 따른 화합물의 용도.
  12. a) 일반식(Ⅲ)화합물을 일반식(Ⅳ) 화합물과 반응시키거나, b) n 이 C인 일반식(Ⅰ)의 화합물을 임의로 반응시켜 n 이 1인 일반식(Ⅰ)의 화합물을 수둑함을 특징으로 하는 제1항에 따른 화합물의 제조방법.
    상기식에서 n, R1, R2, R3, R4및 A 는 상기에 정의된 바와같다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880015210A 1987-11-20 1988-11-18 3-[4-(1-치환된-4-피페라지닐)부틸]-4-티아졸리디논, 이의 제조방법 및 이를 포함하는 약제학적 조성물 KR0130976B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12362287A 1987-11-20 1987-11-20
US123,622 1987-11-20
US123.622 1987-11-20

Publications (2)

Publication Number Publication Date
KR890008137A true KR890008137A (ko) 1989-07-10
KR0130976B1 KR0130976B1 (ko) 1998-04-16

Family

ID=22409774

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880015210A KR0130976B1 (ko) 1987-11-20 1988-11-18 3-[4-(1-치환된-4-피페라지닐)부틸]-4-티아졸리디논, 이의 제조방법 및 이를 포함하는 약제학적 조성물

Country Status (20)

Country Link
US (5) US4933453A (ko)
EP (1) EP0316723B1 (ko)
JP (1) JP2617546B2 (ko)
KR (1) KR0130976B1 (ko)
AT (1) ATE81123T1 (ko)
AU (1) AU624092B2 (ko)
CA (1) CA1317955C (ko)
DE (1) DE3875073T2 (ko)
DK (1) DK645688A (ko)
ES (1) ES2052675T3 (ko)
FI (1) FI89916C (ko)
GR (1) GR3006698T3 (ko)
HU (1) HU206709B (ko)
IE (1) IE62229B1 (ko)
IL (1) IL88414A (ko)
NO (1) NO176143C (ko)
NZ (1) NZ226999A (ko)
PH (1) PH27330A (ko)
PT (1) PT89020B (ko)
ZA (1) ZA888651B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801186A (en) 1987-11-20 1998-09-01 Hoechst Marion Roussel, Inc. 3- 4-(1-substituted-4-piperazinyl)butyl!-4-thiazolidinone and related compounds
EP0316723B1 (en) * 1987-11-20 1992-09-30 Hoechst-Roussel Pharmaceuticals Incorporated 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments
WO1991000863A1 (en) * 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
HU205092B (en) * 1989-11-24 1992-03-30 Richter Gedeon Vegyeszet Process for producing new thiazolidinone derivatives and pharmaceutical compositions comprising same
US5216002A (en) * 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
US5034392A (en) * 1990-04-16 1991-07-23 Hoechst-Roussel Pharmaceuticals Incorporated 4-(3-(4-oxothiazolidinyl)butynylamines
US5041445A (en) * 1990-05-21 1991-08-20 Hoechst-Roussel Pharmaceuticals Incorporated 3-[1-thiazolidinylbutyl-4-piperazinyl]-1H-indazoles
US5045546A (en) * 1990-10-26 1991-09-03 Hoechst-Roussel Pharmaceuticals Inc. 8-azabicyclo[3.2.1]octylalkylthiazolidines
US5194436A (en) * 1991-01-10 1993-03-16 Hoechst-Roussel Pharmaceuticals Inc. 1-piperazinyl-2-butenes and -2-butynes
US5130315A (en) * 1991-01-10 1992-07-14 Raymond R. Wittekind 1-piperazinyl-2-butenes and -2-butynes
US5240927A (en) * 1992-05-19 1993-08-31 Hoechst-Roussel Pharmaceuticals Incorporated Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
AU664084B2 (en) * 1992-06-03 1995-11-02 Ciba-Geigy Ag Novel thiosemicarbazonic acid esters
US5272148A (en) * 1992-09-09 1993-12-21 Hoechst-Roussel Pharmaceuticals Incorporated Heteroarenylpiperazines
CN1050604C (zh) * 1993-02-04 2000-03-22 明治制果株式会社 具有抗精神病作用的化合物
US5391570A (en) * 1993-10-14 1995-02-21 Bristol-Myers Squibb Aminomethyl-benzodioxane and benzopyran serotonergic agents
CA2157348A1 (en) * 1994-09-01 1996-03-02 Aventis Pharmaceuticals Inc. 3-¬4-(1-substituted-4-piperazinyl)butyl|-4-thiazolidinone and related compounds
KR960022486A (ko) * 1994-12-29 1996-07-18 김준웅 신규 티아졸리딘-4-온 유도체
PT732332E (pt) * 1995-03-17 2002-06-28 Aventis Pharma Inc Benzotienilpiperazinas substituidas sua utilizacao como medicamentos e processos para a sua preparacao
KR970032857A (ko) * 1995-12-29 1997-07-22 김준웅 약제 조성물
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
US6506751B1 (en) 1999-11-12 2003-01-14 Millennium Pharmaceuticals, Inc. Thiazolidinone compounds useful as chemokine inhibitors
US7049146B2 (en) * 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
WO2003008398A1 (en) * 2001-07-16 2003-01-30 Euro-Celtique S.A. Aryl substituted thiazolidinones and the use thereof
US20040131504A1 (en) * 2002-09-17 2004-07-08 Landers James P. Remote temperature sensing of small volume and related apparatus thereof
CA2686525C (en) * 2007-03-29 2012-05-29 Obschestvo S Ogranishennoi Otvetstvennostu "Farmving" An antihistamine antiallergic agent and a method of deriving it
MX2011003533A (es) * 2008-10-02 2011-06-16 Abbott Lab Compuestos novedosos como bloqueadores del canal de calcio.
WO2011115813A1 (en) * 2010-03-18 2011-09-22 Abbott Laboratories Lactam acetamides as calcium channel blockers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2520179A (en) * 1949-02-02 1950-08-29 Sterling Drug Inc 4-thiazolidones and a method for preparation thereof
JPS51125389A (en) * 1975-04-09 1976-11-01 Yoshitomi Pharmaceut Ind Ltd A process for preparing heterocyclic compovnds
US4456756A (en) * 1981-08-03 1984-06-26 Mead Johnson & Company Spirothiazolidinyl piperazine derivatives
US4411901A (en) * 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4619930A (en) * 1985-01-16 1986-10-28 Bristol-Myers Company Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use
GB8512163D0 (en) * 1985-05-14 1985-06-19 Fujisawa Pharmaceutical Co Oxothiazolidine compound
EP0316723B1 (en) * 1987-11-20 1992-09-30 Hoechst-Roussel Pharmaceuticals Incorporated 3-[4(1-Substituted-4-piperazinyl)butyl]-4-thiazolidinones a process for their preparation and their use as medicaments
US5041445A (en) * 1990-05-21 1991-08-20 Hoechst-Roussel Pharmaceuticals Incorporated 3-[1-thiazolidinylbutyl-4-piperazinyl]-1H-indazoles

Also Published As

Publication number Publication date
GR3006698T3 (ko) 1993-06-30
NO176143B (no) 1994-10-31
US5229388A (en) 1993-07-20
ES2052675T3 (es) 1994-07-16
KR0130976B1 (ko) 1998-04-16
FI885332A0 (fi) 1988-11-17
FI89916B (fi) 1993-08-31
PT89020B (pt) 1993-02-26
US5037984A (en) 1991-08-06
US5136037A (en) 1992-08-04
PH27330A (en) 1993-06-08
EP0316723B1 (en) 1992-09-30
IL88414A0 (en) 1989-06-30
AU624092B2 (en) 1992-06-04
PT89020A (pt) 1988-12-01
EP0316723A1 (en) 1989-05-24
IL88414A (en) 1993-07-08
ZA888651B (en) 1989-09-27
FI89916C (fi) 1993-12-10
DK645688A (da) 1989-05-21
AU2569488A (en) 1989-05-25
HU206709B (en) 1992-12-28
DK645688D0 (da) 1988-11-18
US4933453A (en) 1990-06-12
ATE81123T1 (de) 1992-10-15
NO176143C (no) 1995-02-08
JPH01160975A (ja) 1989-06-23
JP2617546B2 (ja) 1997-06-04
NZ226999A (en) 1991-05-28
IE883463L (en) 1989-05-20
DE3875073T2 (de) 1993-03-11
NO885152D0 (no) 1988-11-18
US5371087A (en) 1994-12-06
CA1317955C (en) 1993-05-18
NO885152L (no) 1989-05-22
IE62229B1 (en) 1995-01-11
DE3875073D1 (ko) 1992-11-05
HUT54149A (en) 1991-01-28
FI885332A (fi) 1989-05-21

Similar Documents

Publication Publication Date Title
KR890008137A (ko) 3-[4(1-치환된-4-피페라지닐)부틸]-4-티아졸리디노 이의 제조방법 및 약제로서의 이의 용도
DK89595A (da) Fremgangsmåde til fremstilling af 1-(3-dimethylaminopropyl)-1'-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonnitril
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
KR880002834A (ko) α-알킬-4-아미노-3-퀴놀린메탄올 및 1-(4-아르알킬아미노-3-퀴놀리닐) 알칸온, 이의 제조방법 및 약제로서의 용도
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PH20072A (en) Anti-hypertensive 1-substituted spiro-(piperidine-oxobenzoxazine)s
DK0615549T3 (da) Fremgangsmåde til fremstilling af farmaceutisk aktive thiazolidin- eller oxazolidinforbindelser med en gærreduktase
KR900016199A (ko) 티아졸 유도체, 그의 제조방법 및 당뇨병 합병증 치료에 있어서의 그의 용도
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
KR930000483A (ko) [(아릴알킬피페리딘-4-일)메틸]-2a,3,4,5-테트라 하이드로-1(2H)-아세나프틸렌-1-온 및 관련 화합물, 이의 제조방법 및 약제로서의 이의 용도
KR890014522A (ko) 사이클릭 이미드의 아릴피페라지닐알콕시 유도체, 이의 제조방법 및 약제로서의 이의 용도
KR890003730A (ko) 1-페닐-3-(1-피페라지닐)-1h-인다졸, 그의 제조방법 및 중간생성물, 및 약제로서의 용도
KR960704878A (ko) 광학 활성 이미다졸리딘온 유도체 및 이의 제조방법 (Optically active imidazolidinone derivative and process for producing the same)
KR880006203A (ko) 융합된 헤테로사이클릭 테트라하이드로아미노 퀴놀리놀 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
KR910000652A (ko) (1,2,3,4-테트라하이드로-9-아크리딘이미노) 사이클로헥산 카복실산 및 관련 화합물, 이들의 제조방법 및 약제로서의 용도
NO178025C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive (benzhydryloksyetylpiperidyl)alifatiske syrederivater
ES2106439T3 (es) 5-(piperazinilalquil)-1,5-benzotiazepinonas utiles como antagonistas de calcio.
ES8304120A1 (es) Un procedimiento para la preparacion de nuevos derivados de acilaminoquimazolina.
KR940005621A (ko) 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도
ES2174077T3 (es) Derivados de hidroxilamina antiisquemicos y composiciones farmaceuticas.
KR910000744A (ko) 4,5,5a,6-테트라하이드로-3H-이속사졸로[5,4,3-kl]아크리딘 유도체, 이의 제조 방법 및 약제로서의 이의 용도
KR910018367A (ko) 4-[3-(4-옥소티아졸리디닐)]부티닐아민, 이의 제조방법 및 약물로서 이의 용도
KR920006355A (ko) 2-(4-피페리디닐)-1-H-피리도[4,3-b]인돌-1-온 및 관련화합물, 이의 제조를 위한 중간체 및 이의 제조방법
KR900001696A (ko) 궤양치료 활성을 갖는 1.4-디아제핀 유도체
FI871253A (fi) 1-/3-(2-dialkylaminoetoxi)-2 -tienyl/-3-fenyl-1-propanoner och deras syraadditionssalter, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska sammansaettningar.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20021114

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee